Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTA-121 (Oxytocin) for Autism Spectrum Disorder
NCT03466671Phase 2Unknown
- Sponsor
- Hamamatsu University School of Medicine
- Start
- Feb 2018
- Primary completion
- Mar 2020
- Countries
- 1
01
Overview
A Phase 2 trial of oxytocin nasal spray in Autism Spectrum Disorder (ASD), sponsored by Hamamatsu University School of Medicine. Status: unknown.
02
Drugs
oxytocin nasal spray
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03466671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466671.